Market Cap | 40.48M | P/E | - | EPS this Y | 40.50% | Ern Qtrly Grth | - |
Income | -51.6M | Forward P/E | -1.03 | EPS next Y | -41.20% | 50D Avg Chg | -15.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -24.00% |
Dividend | N/A | Price/Book | 1.35 | EPS next 5Y | - | 52W High Chg | -58.00% |
Recommedations | 2.00 | Quick Ratio | 0.66 | Shares Outstanding | 9.54M | 52W Low Chg | 76.00% |
Insider Own | 18.62% | ROA | -57.56% | Shares Float | 7.72M | Beta | 1.54 |
Inst Own | 8.26% | ROE | -222.44% | Shares Shorted/Prior | 136.52K/389.03K | Price | 4.96 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 50,262 | Target Price | 17.50 |
Oper. Margin | - | Earnings Date | May 10 | Volume | 13,769 | Change | -1.39% |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Cantor Fitzgerald | Overweight | Aug 24, 23 |
HC Wainwright & Co. | Buy | Aug 16, 23 |
BTIG | Buy | Aug 15, 23 |
HC Wainwright & Co. | Buy | Aug 15, 23 |
BTIG | Buy | Jun 16, 23 |
HC Wainwright & Co. | Buy | Jun 16, 23 |
HC Wainwright & Co. | Buy | May 15, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Litchman Manuel MD | President and CEO President and CEO | Dec 22 | Buy | 2.91 | 100,000 | 291,000 | 654,846 | 12/22/20 |